Predict your next investment

Incubator/Accelerator
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Management & Strategy Consulting
csaccelerator.com

See what CB Insights has to offer

Investments

64

Portfolio Exits

4

About Cedars-Sinai Accelerator

Cedars-Sinai Accelerator is transforming heatlhcare quality, efficiency, and care delivery by helping entrepreneurs bring their innovative technology products to market. This three-month program, based in Los Angeles, California, provides companies with $120,000 in funding, mentorship from more than 300 leading clinicians and executives, access to Cedars-Sinai, and exposure to a network of over 10,000 entrepreneurs and investors.

Cedars-Sinai Accelerator Headquarter Location

8601 Beverly Boulevard

Los Angeles, California, 90048,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cedars-Sinai Accelerator Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cedars-Sinai Accelerator Rank

Latest Cedars-Sinai Accelerator News

Innovative app found to be as good as gastroenterologists at characterizing stool samples

May 20, 2022

An innovative mobile phone application was found to be as good as expert gastroenterologists at characterizing stool specimens, according to a study by Cedars-Sinai. The artificial intelligence (AI) used in the smartphone app also outperformed reports by patients describing their stool specimens. Stool reporting by patients, usually guided by the Bristol Stool Scale, is crucial to helping physicians evaluate symptoms for diagnosis or for judging the effectiveness of medications. Sometimes patients don't know what is normal or abnormal when trying to characterize a bowel movement. This app takes out the guesswork by using AI, not patient input, to process the images taken by the smartphone." Mark Pimentel, MD, principal investigator of the study, executive director of the Medically Associated Science and Technology Program at Cedars-Sinai Related Stories "The mobile app produced more accurate and complete descriptions of constipation, diarrhea and normal stools than a patient could and was comparable to specimen evaluations by well-trained gastroenterologists in the study," said Pimentel, a specialist in irritable bowel syndrome (IBS). The validation study, was published in the American Journal of Gastroenterology and will be presented at the Digestive Disease Week conference in San Diego on May 21. Investigators used a trained AI app for smartphones developed by Dieta Health, a graduate of the Cedars-Sinai Accelerator program that helps entrepreneurs bring their innovative healthcare technology products to market. In a randomized controlled study, participants with diarrhea-predominant IBS, or IBS-D, were asked to use the AI app to take a picture of every stool for two weeks. In addition to the commonly used Bristol Stool Scale, the AI app also incorporates additional classification parameters. Two expert gastroenterologists assessed the images to validate the mobile app. "The artificial intelligence tool removes the subjective description that can be part of a patient's description of their bowel specimens. In addition to improving a physician's ability to assess their patients' digestive health, this app could be advantageous for clinical trials by reducing the variability of stool outcome measures," said Ali Rezaie, MD, co-author of the study and the medical director of GI Motility at Cedars-Sinai. Source:

Cedars-Sinai Accelerator Investments

64 Investments

Cedars-Sinai Accelerator has made 64 investments. Their latest investment was in Rhaeos as part of their Seed VC on December 12, 2021.

CBI Logo

Cedars-Sinai Accelerator Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/24/2021

Seed VC

Rhaeos

$2.2M

No

6

9/28/2021

Convertible Note

EpiBone

$0.1M

Yes

1

9/28/2021

Convertible Note

inTandem Health

$0.1M

Yes

1

9/28/2021

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

9/28/2021

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/24/2021

9/28/2021

9/28/2021

9/28/2021

9/28/2021

Round

Seed VC

Convertible Note

Convertible Note

Convertible Note

Convertible Note

Company

Rhaeos

EpiBone

inTandem Health

Subscribe to see more

Subscribe to see more

Amount

$2.2M

$0.1M

$0.1M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

1

10

10

Cedars-Sinai Accelerator Portfolio Exits

4 Portfolio Exits

Cedars-Sinai Accelerator has 4 portfolio exits. Their latest portfolio exit was Enso Relief on March 09, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/9/2021

Acquired

4

2/17/2021

Acquired

Subscribe to see more

Subscribe to see more

10

3/17/2020

Acquired

Subscribe to see more

Subscribe to see more

10

2/14/2019

Acquired

Subscribe to see more

Subscribe to see more

10

Date

3/9/2021

2/17/2021

3/17/2020

2/14/2019

Exit

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.